



Corporate Headquarters
Hikma Pharmaceuticals USA Inc.
200 Connell Drive 4th Floor
Berkeley Heights, NJ 07922

T 1.908.673.1030 F
1.908.673.1042

May 10, 2021

The Honorable Henry McMaster
Governor, State of South Carolina

Alan Wilson
Attorney General

Bryan Stirling
Head, Department of Corrections

RECEIVED

Jun 08 2021

S.C. SUPREME COURT

RECEIVED

JUN 07 2021

DIRECTOR

Dear Governor McMaster, Mr. Wilson, and Mr. Stirling:

Hikma is a global pharmaceutical company committed to improving patient lives by providing access to high quality, affordable medicines. Our medicines are used by medical professionals and patients millions of times each day to treat illness and save lives. This has been our mission for more than 40 years.

As Hikma has done in past years, I am writing to remind you of our objection in the strongest possible terms to the use of any of our products for lethal injection and to request confirmation in writing that the state of South Carolina or any facility run directly by the state of South Carolina is not in possession of any Hikma/West-Ward products that it intends to use for capital punishment.

Despite our best efforts to ensure our medicines are used only for their intended medicinal purposes, including a requirement that they only be supplied to pre-authorized customers who agree not to sell them to Departments of Correction or other entities that intend to use them for capital punishment, some states continue to attempt to procure our products from distributors and other intermediaries for this purpose. Not only is this contrary to our intention of manufacturing medicines for the health and well-being of patients in need, but also it is completely counter to our company values.

As a result, we have had to extend the restriction of products to include a broad range of medicines. This list of restricted products is kept current on our website at www.hikma.com. We would like to make clear that our objection to the use of our medicines in capital punishment should be applied to all our products, whether manufactured within or outside the US.

We also request that the Director and other relevant South Carolina Department of Corrections officials not circumvent our carefully prepared controls or take any actions that would undermine the specially drafted legal provisions in our agreements. In the event we are forced to implement additional controls to prevent diversion and misuse of our medicines, such action may have the unintended consequence of potentially preventing certain patients from receiving these medicines despite having a genuine medical need. This outcome would not be beneficial for anyone, particularly the good people of South Carolina.

High quality, generic medicines play a vital role in improving health. As such, we hope you will be our partner in furthering our values and upholding our policy prohibiting the use of our medicines in capital punishment.



Corporate Headquarters
Hikma Pharmaceuticals USA Inc.
200 Connell Drive 4th Floor
Berkeley Heights, NJ 07922

T 1.908.673.1030 F
1.908.673.1042

Kindly respond to this request by June 11, 2021.

Thank you.

Steven H. Weiss
Head of US Communications and Public Affairs
sweiss@hikma.com
